Shares of Swiss biotech firm Santhera Pharmaceuticals (SIX: SANN) were up 26.75% to 10.14 Swiss francs in early trading, after the company announced a COVID-19 related collaboration.
Santhera has joined forces with Cold Spring Harbor Laboratory (CSHL) to investigate lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome (ARDS), a frequent result of the novel coronavirus.
The company acquired rights to POL6014 in 2018 from fellow Swiss firm Polyphor, in a deal that involved an upfront payment of around $7 million plus additional cash payments of up to 121 million francs ($124 million) contingent on future development, regulatory and particularly sales milestones
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze